GLP-3 8 mg per ml wB/12 or w/o B12
- FormatInjectables
- SKUINJGLP3RETA
Wholesale Pricing Available
Register for a wholesale account to view pricing, place bulk orders, and access volume discounts.
About this product
GLP-3 8 mg per ml wB/12 or w/o B12 is supplied at 24 mg/ 3 ml. [Per-product description to be added.]
Suggested use: Provider establish dose. Inject weekly
Investigational Compound: Retatrutide (GLP-3) is currently in Phase 3 clinical trials. It has not received FDA approval and is not available for general commercial use. This page is for educational purposes only. Availability through our practice is subject to physician review and applicable regulations.
What It Does
Six Reasons Clinicians Are Watching Retatrutide (GLP-3)
The first triple-hormone receptor agonist — simultaneously targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical trial data published in the New England Journal of Medicine showed up to 24.2% body weight reduction over 48 weeks — the largest weight loss effect ever recorded for a pharmacological agent in a randomized controlled trial.
GLP-1 Receptor
Reduces appetite, slows gastric emptying, improves insulin secretion, lowers blood glucose — the mechanism shared with semaglutide and tirzepatide
GIP Receptor
Enhances insulin sensitivity, supports fat tissue metabolism, amplifies GLP-1 effects, and improves nutrient storage efficiency in non-adipose tissue
Glucagon Receptor
Increases energy expenditure, directly stimulates fat breakdown in the liver and adipose tissue, and drives thermogenesis — the metabolic accelerator that separates Retatrutide from dual agonists
Unprecedented Weight Loss Efficacy
Phase 2 trial data published in the NEJM demonstrated a mean body weight reduction of 17.5% at the lowest therapeutic dose and up to 24.2% at the highest dose over 48 weeks — surpassing semaglutide (15%), tirzepatide (21%), and every other pharmacological weight loss agent tested in a randomized controlled trial to date. Participants had not reached a weight loss plateau at 48 weeks, suggesting even greater reductions are achievable with longer treatment duration.
Directly Increases Energy Expenditure
The glucagon receptor component is Retatrutide's most important differentiator from semaglutide and tirzepatide. Glucagon receptor activation directly stimulates thermogenesis — increasing the body's basal metabolic rate and rate of fat oxidation independent of caloric intake. This means Retatrutide doesn't just reduce calories in through appetite suppression — it simultaneously increases calories out through enhanced metabolic activity, attacking energy balance from both sides simultaneously.
Dramatic Visceral Fat Reduction
Trial data showed exceptional reductions in visceral adipose tissue — the metabolically dangerous fat surrounding abdominal organs that drives cardiovascular disease, insulin resistance, and systemic inflammation. Glucagon receptor activation specifically targets hepatic and visceral fat for preferential oxidation, producing disproportionately large reductions in this highest-risk fat depot compared to subcutaneous fat — an outcome more clinically meaningful than total body weight reduction alone.
Comprehensive Metabolic Improvement
Beyond weight loss, trial participants showed significant improvements across the full metabolic syndrome panel — including fasting glucose, HbA1c, triglycerides, LDL cholesterol, blood pressure, and insulin sensitivity. The triple-receptor mechanism addresses metabolic dysfunction at more points simultaneously than any single or dual agonist, producing a more complete metabolic reset that addresses the cardiovascular and metabolic risk factors that accompany obesity beyond weight alone.
Once-Weekly Dosing
Retatrutide is designed for once-weekly subcutaneous injection — the same dosing schedule as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). The once-weekly format maximizes adherence by removing daily dosing burden while maintaining consistent receptor activation throughout the week. The drug's pharmacokinetic profile was specifically engineered to produce stable weekly plasma concentrations without the peaks and troughs that can amplify side effects with shorter-acting formulations.
Outperforms Every Existing GLP-1 Agent
In head-to-head comparisons with historical trial data, Retatrutide's weight loss outcomes exceed semaglutide by approximately 9 percentage points and tirzepatide by approximately 3 percentage points in mean body weight reduction. Its NASH (non-alcoholic steatohepatitis) data shows dramatic liver fat reduction. Early cardiovascular endpoint data mirrors the cardiovascular risk reduction seen with established GLP-1 agents — suggesting Retatrutide may deliver superior weight loss while maintaining the same cardiometabolic protective benefits.
Phase 3 Clinical Trials Currently Underway
Retatrutide is being developed by Eli Lilly and is currently in large-scale Phase 3 trials evaluating weight loss, cardiovascular outcomes, and type 2 diabetes management. FDA approval is anticipated pending trial completion and regulatory review. Availability through physician-supervised protocols is subject to applicable regulations at the time of your consultation. Contact us to be notified when this becomes available.
* These statements have not been evaluated by the Food and Drug Administration. Retatrutide is an investigational compound not approved by the FDA. This content is for educational purposes only and does not constitute medical advice or a claim of product availability.
Formulated by Dr. Sasson Moulavi
Every Lavi MD peptide is developed under the direction of Dr. Sasson Moulavi, the physician behind the brand. Formulations are built to clinical specification, not sourced from anonymous suppliers.
Dr. Moulavi earned his Doctor of Medicine from the University of Toronto and completed postgraduate training at McGill University in Montreal. He holds Board Certification in Anti-Aging Medicine and Bariatric Medicine, and is a member of the American Academy of Anti-Aging Medicine and the American Society of Bariatric Physicians. With over three decades of clinical experience in bariatric, family, and anti-aging medicine, he serves as Medical Director and prescribing physician for Lavi MD, overseeing formulation standards and clinical protocols.
Simple, invoice-based ordering
No card is charged on this site. You build a request, we confirm it, and you pay a proper invoice. Built for how clinics and pharmacies actually buy.
Browse & build
Add products to your order request at wholesale pricing. No payment required.
Submit request
Send your request to our team. We review availability and confirm your order.
Get invoiced
You receive a QuickBooks invoice for the confirmed order and pay securely there.
Cold-chain ship
Once paid, your order is fulfilled and shipped cold-chain by our team.
Why Lavi MD
Not All Peptide Brands Are Equal
Most peptide suppliers prioritize volume over patients. We were built differently — by a physician, for patients.
Brands / Suppliers
Medical Director on Staff
Sasson Moulavi, MD
Dispensing Physician · Chayim Therapeutics, LLC
West Palm Beach, FL
"Every product we offer is something I would prescribe to my own patients. Our formulations are designed for clinical outcomes — not marketing claims."
How We Operate
Built by a Physician, Not a Marketing Team
Lavi MD was founded under physician supervision. Every formulation, every dose, every protocol is reviewed by Dr. Moulavi before it reaches a patient — not outsourced to a contract manufacturer with no clinical input.
We Limit Shipping Days to Protect Your Product
We only ship Monday and Tuesday. That's a deliberate decision — it ensures your order arrives before the weekend and never sits in a carrier facility over two days without refrigeration. Most brands don't think that far ahead.
We Treat You Like a Patient, Not an Order Number
Our team includes clinical staff who understand what you're taking and why. If something goes wrong with your order — a warm shipment, a missing component, a question about your protocol — we fix it. No automated runaround.
Proud Members of the
American Peptide Association
The American Peptide Association is the leading industry body advancing the science, safety, and standards of peptide research. Our membership reflects our unwavering commitment to purity, transparency, and responsible sourcing — giving you full confidence in every product you purchase.
